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Abstract  39 
 
 
Background Antimicrobial resistance in invasive infections is driven mainly by human 40 
antimicrobial consumption.  Limited cross-national comparative evidence exists about 41 
variation in antimicrobial consumption and effect on resistance.  42 
Methods and Findings We examined the relationship between national community 43 
antimicrobial consumption rates (2013) and national hospital antimicrobial resistance rates 44 
(2014) across 29 countries in the European Economic Area (EEA). Consumption rates were 45 
obtained from European Surveillance of Antimicrobial Consumption Network (ESAC-Net). 46 
Resistance data were obtained from European Antimicrobial Resistance Surveillance 47 
Network (EARS-Net), based on 196,480 invasive isolates in 2014. Data availability and 48 
consistency were good. Some countries did not report figures for each strain of resistant 49 
bacteria. National antimicrobial consumption rates (2013) varied from <13DDD (Estonia, 50 
Netherlands, and Sweden) to ≥30 DDD (France, Greece, Romania) per 1000 population/day. 51 
National antimicrobial resistance rates (hospital isolates, 15 species) also varied from <6.1% 52 
(Finland, Iceland, Sweden) to >37.2% (Bulgaria, Greece, Romania, Slovakia). National 53 
antimicrobial consumption rates (2013) showed strong to moderate correlation with 54 
national hospital antimicrobial resistance rates (2014) in 19 strains of bacteria (r=0.84 to 55 
r=0.39).  Some countries defied the trend with high consumption and low resistance 56 
(France, Belgium, Luxembourg) or low consumption and high resistance (Bulgaria, Hungary, 57 
Latvia).  58 
Conclusions We found associations between national community antimicrobial 59 
consumption and national hospital antimicrobial resistance across a wide range of bacteria. 60 
These associations were not uniform. Different mechanisms may drive resistance in 61 
hospital-based invasive infections. Future research on international variations in 62 
 
 
antimicrobial resistance should consider environmental factors, agricultural use, vaccination 63 
policies and prescribing quality.  64 
65 
 
 
Introduction 66 
Antimicrobial resistance is a serious global threat to public health. Increasing human 67 
antimicrobial consumption is widely considered to be highly influential, with agricultural 68 
use, environmental pollution, clonal and horizontal spread and long-term persistence also 69 
contributory.1 ,2 Recent evidence comes from meta-analyses that report positive 70 
associations between antimicrobial consumption and the development of resistance at both 71 
population and individual levels.3 ,4  72 
 73 
Across Europe, there is wide variation at national level in both antimicrobial resistance and 74 
consumption. In general, lower rates of antimicrobial resistance are found in northern 75 
European countries and higher rates of resistance found in southern European countries.5 76 
Previous studies have found strong correlations between specific antimicrobial consumption 77 
and resistances but have only studied a limited number of resistant strains of bacteria, 78 
mainly Streptococcus, Staphylococcus and Escherichia coli.4-6  A systematic review and meta-79 
analysis of 243 studies examined both population and individual level data, mainly in 80 
Europe.4 It confirmed a positive relationship between antimicrobial consumption and 81 
resistance (pooled effect size (odds ratio) of 2.3 (95% CI 2.2 – 2.5)), although this was only 82 
observed for enteric bacteria and Streptococcus. The authors were not able to identify 83 
factors consistently predictive of this relationship.4  84 
 85 
The aim of this study was to evaluate the relationship between antimicrobial consumption 86 
and resistance across Europe, with focus on a wide range of resistant bacteria.  87 
 88 
Methods 89 
 
 
Study Design 90 
This was a cross-sectional study of routinely collected data comparing national community 91 
level antimicrobial consumption rates and national hospital antimicrobial resistance rates 92 
across 29 countries in the European Economic Area (EEA).  93 
 94 
Data sources, measures and procedures 95 
We compared antimicrobial consumption rates in 2013 with antimicrobial resistance rates 96 
in 2014 in order to reflect a 1-year time lag between antimicrobial use and the subsequent 97 
development of resistance, in accordance with previous studies.5 ,7 We used national data 98 
for antimicrobial consumption from ESAC-Net, an interactive online database which 99 
provides European reference data on antimicrobial consumption from hospital and 100 
community settings.8 The reports from the database are published by the European 101 
Surveillance System (TESSy).9 In 2013, antimicrobial consumption data were available for 30 102 
European countries in the EEA. Most countries based their antimicrobial consumption data 103 
on community or primary care data (i.e. outside of hospital). Cyprus, Iceland and Romania 104 
provided combined community and hospital antimicrobial consumption data only. 105 
Approximately 90% of national antimicrobial consumption is based in the community so the 106 
figures provided for these three countries may overestimate community consumption. 10 107 
Data were obtained for the years 2009-2013 to allow annual fluctuations in antimicrobial 108 
consumption to be observed. Data were provided in the form of DDD per 1000 inhabitants 109 
per day. DDD, as defined by the WHO, is the assumed average treatment dose per day for a 110 
drug prescribed for its main indication in adults.11 Drugs that have been assigned a code in 111 
the Anatomical Therapeutic Chemical (ATC) classification system were assigned a DDD. The 112 
national antimicrobial consumption figures refer to ATC group J01 (antibacterials for 113 
 
 
systemic use). Data sources included either sales or reimbursement figures or both and 114 
varied by country. Sales data include sales of antimicrobials obtained without a prescription. 115 
Full details of data sources can be found on the ECDC website.8 116 
 117 
The main outcome measures were antimicrobial resistance levels in 2014. We obtained 118 
these data from the EARS-Net interactive database, also provided through TESSy.12 119 
Antimicrobial resistance data in the EARS-Net database were exclusively based on invasive 120 
isolates from blood or CSF and were collected through a voluntary network of national 121 
surveillance systems in each participating country from 900 laboratories serving 1400 122 
hospitals. National data were uploaded directly by the national data manager to TESSy on a 123 
yearly basis. 13 Isolates have been reported consistently to EARS-Net by most countries since 124 
2003. Specific resistance levels were only reported if at least 10 isolates per country for the 125 
bacterial species in question were tested. We looked at data on all antimicrobial resistant 126 
strains that were collected by TESSy (26 strains in total: see Table 2), including resistant 127 
strains of Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella 128 
pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus 129 
pneumoniae. 130 
 131 
We developed a value for resistance and consumption for each country. The resistance 132 
‘value’ was the mean rate of hospital antimicrobial resistance per country for 2014. This 133 
value included the 15 resistant strains of bacteria which showed a positive correlation 134 
(r=>0.3) with overall antimicrobial consumption that were available for every country (Table 135 
1: included strains in bold). The consumption ‘value’ was the overall national consumption 136 
rate (ATC J01 group) reported by the ECDC for 2013 (DDD per 1000 inhabitants per day) 137 
 
 
(Supplementary Table 1, available online). We then developed a ratio of mean antimicrobial 138 
resistance to overall antimicrobial consumption per country to describe the pattern of the 139 
association between high antimicrobial consumption and high resistance, and to identify 140 
outliers in this association. 141 
   142 
Statistical methods 143 
We assessed the correlation (Pearson’s r) between overall antimicrobial consumption and 144 
antimicrobial resistance for 29 European countries. Firstly, we assessed correlation between 145 
overall antimicrobial consumption and resistance rates for each organism (n=26). We then 146 
assessed correlation between antimicrobial consumption values for the antibiotic class 147 
specific to the resistant strain and the rates of resistance in that strain. Finally, we compared 148 
the national mean resistance rates to overall antimicrobial consumption as described above.  149 
 150 
 151 
Results  152 
Antimicrobial consumption data were available for 30 countries for 2013. The Netherlands, 153 
Estonia, and Sweden had the lowest rates of overall antimicrobial consumption in 2013 (≤13 154 
DDD per 1000 inhabitants per day). France, Romania and Greece had the highest (≥30 DDD 155 
per 1000 inhabitants per day). The ranges of consumption rates were wide.  Year to year 156 
variation was small except for Romania between 2009 and 2011.  The overall national 157 
consumption of antimicrobials between 2009 and 2013 is shown in Supplementary Table 1 158 
(available online). The types of antimicrobials used and their rates of use in each EEA 159 
country in 2013 are shown in Supplementary Figure 1 (available online). 160 
 161 
 
 
Resistance data were available for 29 EEA countries for 2014. Data were not available for 162 
Poland. Resistance rates were based on 196,480 invasive isolates in 2014, a mean of 6549 163 
isolates per country (Table 2).  Seven countries reported less than 1000 isolates: Bulgaria 164 
(847), Cyprus (540), Estonia (967), Iceland (299), Latvia (670), Luxembourg (716), and Malta 165 
(299).  Swedish data for E. coli resistant to aminopenicillins were missing in 2014 (2013 data 166 
were used in their place), and Greek data for S. pneumoniae resistant to macrolides were 167 
missing for 2013 and 2014.  168 
 169 
Figure 1 shows the relationship across 29 countries between overall antimicrobial 170 
consumption for 2013 and resistance rates for 2014 in three common pathogenic strains of 171 
bacteria: E. coli resistant to aminopenicillins; MRSA; and S. pneumoniae resistant to 172 
macrolides. This figure demonstrates the overall trend of lower antimicrobial resistance 173 
associated with lower antimicrobial consumption. Of the three strains, E. coli resistant to 174 
aminopenicillins represented the highest rate of antimicrobial resistance across all 175 
countries.  176 
 177 
Figure 1 178 
 179 
The correlation scores between overall and specific antimicrobial consumption and 180 
resistance rates of each of the 26 resistant strains of bacteria for all countries studied are 181 
shown in Table 1. Strong or moderate correlations were observed between 19 of the 182 
resistant strains and overall antimicrobial consumption. Strong or moderate correlations 183 
were observed between 12 resistant strains and specific antimicrobial consumption 184 
including the 3 pathogenic strains in Figure 1. Of note is the strong correlation between the 185 
 
 
consumption of fluoroquinolones and rates of resistance of E. coli to fluoroquinolones 186 
(r=0.84, p = <0.001). 187 
 188 
Table 1 189 
 190 
Table 2 shows the ratios of mean national antimicrobial resistance to overall national 191 
antimicrobial consumption. Mean national antimicrobial resistance rates were highest in 192 
Romania (45.9%) followed by Slovakia (40.3%) and Greece (37.8%). Iceland, Finland and 193 
Sweden had the lowest mean antimicrobial resistance rates (5.3%, 5.9% and 6.7%, 194 
respectively). France, Belgium and Luxembourg, each with high rates of consumption, had 195 
low rates of mean antimicrobial resistance. Latvia, Bulgaria and Hungary, each with low 196 
rates of consumption had high rates of antimicrobial resistance. Total antimicrobial 197 
consumption (all countries) was moderately correlated with mean resistance (all countries) 198 
(r= 0.54, p = 0.003) (see Figure 2). The inclusion of all resistant strains available for each 199 
country in the analysis, regardless of whether there was a positive correlation with overall 200 
consumption, did not alter the results.  201 
 202 
Table 2 203 
 204 
Figure 2  205 
 206 
 207 
Discussion  208 
We found moderate to strong correlations between rates of overall community 209 
antimicrobial consumption and hospital antimicrobial resistance rates across 29 European 210 
countries, with respect to 19 strains of resistant bacteria; significant correlation was not 211 
 
 
found for the remaining 7 resistant strains included in our study. We also found moderate 212 
to strong correlations between specific community antimicrobial consumption and 213 
resistance rates with respect to 12 out of 23 strains of resistant bacteria for which we could 214 
access data. In addition, we discovered significant disparities across Europe when comparing 215 
national ratios of mean resistance (incorporating 15 strains of resistant bacteria) to overall 216 
antimicrobial consumption.  217 
 218 
Our study confirms the relationship between community antimicrobial consumption and 219 
serious resistant infections in patients in hospital. It is striking that the antibiotics were 220 
prescribed (and most likely consumed) in the community but the bacterial resistance 221 
reported was found in invasive hospital specimens from blood or CSF. Our study was unable 222 
to determine whether the infections were acquired in hospital or the community. Resistant 223 
strains often emerge within hospital due to the frequent use of broad-spectrum antibiotics 224 
as well as the proximity of patients to each other and healthcare workers.  225 
 226 
Our findings emphasise the importance of reducing antibiotic consumption in the 227 
community at national level to limit resistance in serious hospital infections. The strongest 228 
correlations were seen between total national antimicrobial consumption and MRSA, 229 
carbapenem resistant K. pneumoniae, and macrolide resistant S. pneumoniae. Regarding 230 
correlations between specific antibiotic consumption and species resistance (i.e. a specific 231 
antibiotic and an organism resistant to that antibiotic) strongest correlations were seen for 232 
fluoroquinolone resistant E coli, aminoglycoside resistant P.aeruginosa, and E. coli resistant 233 
to third generation cephalosporins.  Many of these associations accord with earlier studies. 234 
5,6 We found no correlation between consumption of beta lactams and S. pneumoniae 235 
 
 
resistant to penicillins in contrast to previous studies (Goossens et al: 2000-1 data, 236 
Spearman’s rho = 0.84 (0.62-0.94), 19 countries 5; Van de Sande Bruisma et al: 2003-4 data, 237 
Pearson’s r = 0.78 (0.48-0.92), 17 countries 6). Both studies looked at a smaller number of 238 
countries than the present study, and during an earlier time-frame.  239 
 240 
Our study found striking exceptions to the previously reported international pattern of 241 
associations between low antibiotic consumption and low resistance, and high antibiotic 242 
consumption and high resistance. At the time of our analysis, those countries with high 243 
rates of antimicrobial consumption and low rates of resistance (France, Luxembourg and 244 
Belgium) were all high prescribers of beta-lactam antimicrobials (a class of antibiotics which 245 
includes penicillins, amoxicillin, flucloxacillin, cephalosporins and carbapenems), the most 246 
commonly prescribed antibiotics in Europe.10 In the early 2000’s, European campaigns to 247 
reduce overall antimicrobial use 14-16 achieved substantial reductions in prescribing and 248 
were associated with subsequent reductions in antimicrobial resistance, particularly in 249 
penicillin-non-susceptible S. pneumoniae (PNSP). 16 ,17 These campaigns coincided with the 250 
introduction of the Heptavalent Pneumococcal Conjugate Vaccine (PCV7) into the 251 
vaccination schedule in France. 17 ,18 The subsequent widespread use of PCV immunisation 252 
across Europe is considered to have influenced the decrease in penicillin resistance-levels by 253 
eliminating infections with common ‘classic’ resistant serotypes. 13 ,18 This may explain why 254 
we found no correlation between beta lactams and S. pneumoniae resistant to penicillin in 255 
our 2013/14 data. Penicillin resistant streptococci have remained low since 2010.12 PCVs are 256 
part of the vaccination schedule for the majority of European countries but there are 257 
variations in routine systems for monitoring PCV coverage19. It is possible that in countries 258 
where the uptake of vaccination is poor, herd immunity is insufficient to keep population 259 
 
 
levels of resistant S. pneumoniae low. Variations in reporting practices of S. pneumoniae 260 
resistance also decrease our ability to draw meaningful conclusions about the relationship 261 
between consumption and resistance with regards to S. pneumoniae and beta lactam 262 
consumption.13 263 
 264 
Antimicrobial prescribing ‘quality’ may also contribute to the between country discrepancies 265 
observed in the relationship between resistance and consumption rates at national level.20 266 
Quality indicators include factors such as total amount of specific antimicrobials consumed,  267 
ratio between consumption volumes of broad and narrow spectrum antimicrobials, and 268 
seasonal variation of total antimicrobial use and quinolone use.20-22  High rates of resistance 269 
despite low volumes of antimicrobial prescribing were identified in Latvia, Bulgaria and 270 
Hungary. Possible reasons for this discrepancy include high seasonal variation (Hungary), 22 271 
and high use of fluoroquinolones (Hungary and Bulgaria). 21 ,22 Neither of these factors 272 
appear to apply in Latvia, which reported moderate seasonal variation in antimicrobial 273 
consumption. However, high levels of antimicrobial prescribing for upper respiratory tract 274 
infections (usually caused by viruses) and a trend towards using broader spectrum 275 
antimicrobials such as quinolones for uncomplicated urinary tract infection have been 276 
reported from Latvia. 23 Controlling high rates of antimicrobial resistance in countries with 277 
low volumes of consumption may require greater adherence to prescribing guidelines and 278 
formularies.  279 
 280 
The major strength of our study is its size. Using routinely collected data we compared 29 281 
different countries regarding 26 different strains of resistant bacteria. We believe this to be 282 
the most comprehensive investigation so far reported in Europe. Our use of a unique mean 283 
 
 
resistance score offered a novel method for analysing broader national trends, which 284 
allowed us to highlight international discrepancies not previously reported in the literature. 285 
We also believe that using data from invasive samples (blood and CSF) to determine 286 
resistance is an important strength of our study, contributing to greater consistency of 287 
reporting.13 National variations in the number of invasive samples included may reflect 288 
differences between countries in the frequency of use of blood cultures. 289 
 290 
The limitations of our study were mainly related to data availability and comprehensiveness. 291 
Not all countries reported figures for community antimicrobial consumption or for each 292 
strain of resistant bacteria, for every year, although data consistency has improved 293 
greatly.13  294 
 295 
In summary, this study has highlighted the strength of association between total and 296 
specific community consumption rates of antibiotics and resistance rates in up to 20 strains 297 
of resistant bacteria across 29 European countries. The community basis of the observed 298 
antimicrobial consumption rates emphasises the important influence of choice of antibiotic 299 
prescription in the community on the risk of resistance in serious hospital infections. The 300 
discrepancies we identified in this association imply that antimicrobial prescribing quality 301 
contributes to patterns of resistance as well as the volume of consumption. Future work on 302 
international variations in antimicrobial resistance could address the role of environmental 303 
factors, socio-economic status and overcrowding, agricultural antimicrobial practices, as 304 
well as vaccination policies and the quality of prescribing.  305 
 306 
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Table 1. Correlation between overall and specific antimicrobial consumption (2013) and 391 
resistance (2014) across 29 European countries  392 
(descending order of correlation strength) 393 
Resistant species of bacteria1 (2014) 
(ATC2 code of specific antibiotic studied) 
 
Correlation with overall3 (specific4) 
consumption (2013) all countries  
(Pearson’s r) 
MRSA (J01C) 0.64** (0.53**) 
K. pneumoniae resistant to carbapenems (J01DD) 0.58** (ns) 
S. pneumoniae resistant to macrolides (J011FA) 0.56** (0.49**) 
E. coli resistant to fluoroquinolones (J01MA) 0.56** (0.84**) 
E. coli resistant to aminopenicillins (J01C) 0.53** (0.52**) 
E. coli resistant to carbapenems (J01DH) 0.52** (ns) 
P. aeruginosa resistant to amikacin (J01GB06) 0.51** (n/a) 
P. aeruginosa resistant to aminoglycosides 
(J01G) 
0.49** (0.67**) 
K. pneumoniae resistant to fluoroquinolones 
(J01MA) 
0.48** (0.52**) 
E. faecalis resistant to vancomycin (J01X) 0.48** (ns) 
E. coli resistant to 3rd Generation 
cephalosporins (J01DD) 
0.46* (0.55**) 
K. pneumoniae resistant to 3rd generation 
cephalosporins (J01DD) 
0.44* (0.39*) 
Multidrug resistant K. pneumoniae 0.43* (n/a) 
P. aeruginosa resistant to carbapenems (J01DH) 0.42* (ns) 
P. aeruginosa resistant to fluoroquinolones 
(J01MA) 
0.42* (0.47**) 
E. faecium resistant to vancomycin (J01X) 0.41* (0.49**) 
S. aureus resistant to rifampicin (J04AB02) 0.40* (n/a) 
K. pneumoniae resistant to aminoglycosides 
(J01G) 
0.39* (0.5**) 
E. coli resistant to aminoglycosides (J01G) 0.38* (ns) 
P. aeruginosa resistant to piperacillin (J01CA) ns (ns) 
P. aeruginosa resistant to ceftazidime (J01DD) ns (ns) 
S. pneumoniae resistant to penicillins (J01C) ns (ns) 
E. faecalis resistant to high level gentamicin 
(J01GB) 
ns (0.56**) 
E. faecalis resistant to aminopenicillins (J01C) ns (ns) 
E. faecium resistant to aminopenicillins (J01C) ns (ns) 
E. faecium resistant to high level gentamicin 
(J01GB) 
ns (ns) 
ns = result not significant, n/a= data not available 394 
*p<0.05, **p <0.01 395 
1 The numbers of invasive isolates for each species were: S pneumoniae (11,516), S Aureus (43,794), E coli (86,580), 396 
enterococci (22,291), K pneumoniae (20,068), P. Aeruginosa (11,973).   Species in bold are included in mean resistance score 397 
2 ATC = anatomical therapeutic classification 398 
3 All antimicrobial consumption (ATC J01 codes only) 399 
 
 
4 Specific consumption refers to the consumption of the antibiotic to which the organism is resistant. 400 
 401 
 
 
Figure 1 The relationship between consumption and resistance in 3 pathogenic strains of bacteria  402 
The relationship across Europe between total antimicrobial consumption for 2013 and resistance rates for 2014 in 3 pathogenic strains of bacteria: E coli, MRSA, and S. 403 
pneumoniae 404 
 
 
 405 
 406 
 
 
Table 2. National antimicrobial consumption rates (2013) and mean national antimicrobial 407 
resistance rates (2014) per European Country 408 
 409 
Country 
(n= number of isolates 
reported) 
National antimicrobial 
consumption rate1 (2013) 
(DDD per 1000 inhabitants 
per day) 
National mean 
antimicrobial resistance 
rate2 (2014) 
(%) 
Ratio of resistance 
to consumption3 
Bulgaria (847) 19.9 37.2   1.9* 
Slovakia (2,742) 23.6 40.3 1.7 
Latvia (670) 13.5 22.2   1.6* 
Hungary (5,303) 15.6 24.2   1.6* 
Romania4 (1,268) 31.6 45.9 1.5 
Portugal (12,871) 19.6 26.4   1.3* 
Czech rep (7,556) 19.0 25.3   1.3* 
Lithuania (1,351) 18.5 24.5   1.3* 
Croatia (2,480) 21.1 26.8 1.3 
Slovenia (2,591) 14.5 18.4 1.3 
Greece (4,216) 32.2 37.8 1.2 
Italy (9,886) 28.6 32.4 1.1 
Estonia (967) 11.7 12.5 1.1 
Spain (12,042) 20.3 19.4   1.0* 
Cyprus1 (540) 28.3 26.8 0.9 
MEAN (6,549) 20.9 19.30 0.9 
Malta (550) 23.8 20.0 0.8 
Germany (13,856) 15.8 12.4 0.8 
Ireland (5339) 23.8 17.0     0.7** 
Austria (10,603) 16.3 10.6 0.6 
Netherlands (13,237) 10.8 6.9 0.6 
Luxembourg (716) 27.7 17.0    0.6** 
France (23,182) 30.1 18.4     0.6** 
U.K. (15,040) 20.6 11.6 0.6 
Sweden (13,638) 13.0 6.1 0.5 
Belgium (6,531) 29.7 13.6     0.5** 
Denmark (9,718) 16.4 7.5 0.5 
Norway (7,271) 16.2 6.7 0.4 
Finland (8,137) 18.3 5.9 0.3 
Iceland4,a (299) 21.9 5.3 0.2 
1 ATC Code J01 group (antibacterials for systemic use) 410 
2Mean percentage isolate resistance rate, based on 15 species of resistant bacteria (see Table 1) 411 
3 higher ratio values indicate high rates of resistance for a given volume of antibiotic consumption 412 
4Consumption figures based on combined hospital and community data which may overestimate consumption 413 
* – country demonstrates lower than average consumption but higher than average resistance 414 
** – country demonstrates higher than average consumption but lower than average resistance 415 
a Iceland not highlighted as demonstrating higher than average consumption with lower than average resistance as total 416 
care data were used417 
 
 
 Figure 2. Total antimicrobial consumption and mean antimicrobial resistance for 29 European Countries (ordered by ratio of resistance to 418 
consumption) 419 
 420 
 421 
 422 
 423 
 424 
Overall correlation between consumption and resistance r = 0.54, p =0.003; number = 29 425 
Closed circles – overall antibiotic consumption, filled squares –  mean bacterial resistance 426 
 427 
